Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packaging Requirements; Risk of Drug Exposure through Eye or Skin Absorption (Recall Alert)

This recall involves bottles of the prescription drug Evrysdi, a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.  The recalled 100 mL amber bottles have “Evrysdi (risdiplam) for oral solution,” the dosage and “NDC 20242-175-07” on the front of the bottle labels.

Consumers should immediately store Evrysdi in a safe location out of reach and sight of children.  Consumers should inspect the bottle for any leaking.  If it is leaking, contact Genentech for a free replacement.  Consumers can continue to use as directed, as the leakage is not anticipated to impact the safety or efficacy of administered medicine.  If Evrysdi gets on your skin, wash the area with soap and water.  If Evrysdi gets in your eyes, rinse your eyes with water.  Genentech is contacting all known purchasers directly.

Genentech has received 26 reports of leaking bottles.  No injuries have been reported.

Select specialty pharmacies nationwide as a prescribed medicine from August 2020 through the present.  The price of the medication varies based on health insurance terms and other factors.

Genentech, a member of the Roche Group, of South San Francisco, Calif.